THOMAS W. WAKEFIELD, MD

Plain English
This study looked at the differences in the physical properties of blood clots in veins after 7 days compared to 14 days. Researchers used a new model in pigs to create blood clots and found that older clots had a different structure and were tougher; for example, the pressure needed to compress them increased significantly from 35.3% for 7-day clots to 66.6% for 14-day clots. Understanding these differences is important to help improve treatments for patients with chronic blood clots. Who this helps: This helps doctors and researchers working on better treatments for patients with chronic deep vein thrombosis.

Plain English
This study looked at how blood flow is affected in people with iliac vein compression syndrome (IVCS), a condition that affects over 20% of the population and causes pain, swelling, and blood clots in the left leg. The researchers found that in IVCS patients, the blood flow in the left iliac vein was significantly different from the right, with the left side having a mean shear rate of 550 compared to 113 in the right. These findings suggest that the differences in blood flow could explain why IVCS patients are at a higher risk for blood clots. Who this helps: This research benefits patients with IVCS and their doctors by providing insights that may improve treatment and management.

Plain English
The study created a new model to test a procedure called balloon venoplasty, which is used to treat blocked veins in animals, specifically rodents. The researchers found that this model effectively mimics human conditions and allows for various tests on the effects of different treatment balloons, making it easier to study how these treatments help and how they impact vein health. This is important because it can lead to better treatments for people suffering from severe vein issues. Who this helps: Patients with deep vein problems and their doctors.

Plain English
This study looked at how a specific protein called MLL1 affects blood clotting and inflammation in cells during a coronavirus infection. Researchers found that when MLL1 is active, it increases the production of substances that promote clotting and inflammation while also reducing the production of a protein that helps manage the immune response. In human samples from COVID-19 patients, they noticed higher levels of MLL1 and clotting-related factors compared to healthy individuals, suggesting that MLL1 may play a significant role in the dangerous blood clotting complications seen in severe COVID-19 cases. Who this helps: This helps patients with severe COVID-19 and healthcare providers managing their care.

Plain English
This study looked at how a specific medical protocol impacted the risk of serious blood clots, called deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients having treatments for venous issues. Researchers found that the overall risk of DVT/PE was only 1.4%, but patients who had both ablation and phlebectomy faced a higher risk at 2.7%. By using a standard risk assessment and preventive treatment, the study showed that patients had better overall recovery outcomes and suggested that further research is needed to confirm these benefits. Who this helps: This information helps patients undergoing superficial vein treatments and their doctors in assessing and managing clot risks effectively.

Plain English
Researchers studied the blood flow in patients with iliac vein compression syndrome (IVCS) to better understand how it affects blood flow rates. They found that patients with IVCS might have increased blood flow rates, similar to those seen in arteries, especially in the left common iliac vein where compression occurs. This finding is important because it could help improve the diagnosis and treatment of IVCS, particularly for patients who have symptoms but moderate compression. Who this helps: This benefits patients with iliac vein compression syndrome and their doctors.

Plain English
This study looked at whether giving blood-thinning medication (VTE chemoprophylaxis) to patients who had low to moderate risk surgeries could reduce the chances of developing blood clots (VTE) after surgery. The researchers found that out of over 32,000 surgeries, only about 1.5% resulted in blood clots, and providing the medication didn’t significantly lower this rate or affect patient deaths. This matters because it challenges the idea that blood thinners are beneficial for all surgical patients and indicates that they might not be necessary for everyone, potentially leading to more personalized care. Who this helps: Patients undergoing low to moderate risk surgeries.

Plain English
This study looked at how using a tourniquet during surgery for large varicose veins affects patient outcomes. Researchers found that after the procedure, patients showed significant improvements in their venous health scores and reported a better quality of life, with an average blood loss of just 50 mL. This matters because it suggests that using a tourniquet can enhance surgical results while keeping blood loss low. Who this helps: Patients with complex varicose veins can benefit from improved treatment outcomes.

Plain English
This study looked at how gender affects the results and complications of a procedure called endovenous ablation, which treats varicose veins. Researchers analyzed data from nearly 10,000 patients and found that while men saw a greater improvement in their vein severity scores (average score change of -4.46 for men vs. -4.13 for women), women experienced more reduction in overall symptoms (average change of -10.64 for women vs. -9.64 for men) and had fewer complications, like leg infections (0.4% in women vs. 0.7% in men). This is important because it suggests that women may handle this procedure better with fewer risks, which can guide doctors in tailoring their treatment and recommendations. Who this helps: This helps patients, especially women considering varicose vein treatments.

Plain English
This study looked at how extremity venous aneurysms (bulges in veins) are currently managed and what outcomes patients experience. Researchers analyzed data from 66 patients and found that 20% of those with popliteal venous aneurysms also had serious complications like deep vein thrombosis (DVT) or pulmonary embolism (PE). They concluded that larger aneurysms and specific types are more likely to cause these problems, suggesting that surgical intervention is often necessary to prevent such complications. Who this helps: This benefits patients with venous aneurysms, especially those at risk of serious complications.

Plain English
This study looked at a surgical technique called closed plication to treat popliteal vein aneurysms, which are rare swelling in a vein behind the knee. Researchers examined data from 10 patients and found that after the procedure, the average size of the veins shrank significantly from about 2.35 cm to 1.12 cm, with 78% of patients maintaining a normal vein size during an average follow-up of almost 3 years. This is important because it shows that closed plication is a safe and effective treatment that reduces the risk of complications common in other surgical methods. Who this helps: Patients with popliteal vein aneurysms.

Plain English
This study looked at the effectiveness of two treatments for patients with painful varicose veins. It involved 3,375 patients and found that 87.4% experienced improvement in their condition, with those who had both treatments (ablation and phlebectomy) reporting a median improvement of 5 points, compared to a 3-point improvement for those who had the ablation alone. With complications being low and most patients reporting better outcomes, the findings support ongoing coverage for these treatments by insurance. Who this helps: Patients suffering from symptomatic varicose veins.

Plain English
This study looked at the outcomes of a procedure called truncal endovenous ablation in patients who have both deep and superficial vein problems. Out of nearly 5,000 patients, 46% had deep venous reflux, and those patients faced higher complication rates (10.4% compared to 3.0%) and more issues like clot extension. This is important because it highlights that patients with deep venous reflux might experience more complications during treatment, so doctors should discuss these risks clearly before proceeding. Who this helps: This helps patients with vein problems and their doctors when making treatment decisions.

Plain English
This paper studied how the COVID-19 virus increases the risk of dangerous blood clots, known as venous thromboembolism (VTE), in severely ill patients. It found that between 21% and 69% of these patients developed VTE, even when receiving preventive blood-thinning treatments. Understanding this connection is crucial because it can help doctors improve treatment strategies for patients with severe COVID-19 and reduce the risk of life-threatening complications. Who this helps: This helps patients with severe COVID-19 and their healthcare providers.

Plain English
This study investigated how certain components of antisense oligonucleotide (ASO) drugs affect blood platelets, which are important for clotting. Researchers found that exposure to specific nucleic acids made platelets overly sensitive, which could lead to complications like blood clots; for example, the sensitivity of platelets to low doses of a clotting agent increased by 6 to 8 times compared to normal. This is important because understanding these effects could help make ASO treatments safer for patients, especially those with advanced cancer who are at risk of clotting issues. Who this helps: Patients receiving ASO treatments, particularly those with cancer.

Plain English
This research examined the connection between chronic venous disease (CVD) and the risk of serious blood clots, known as venous thromboembolism (VTE), which includes conditions like deep vein thrombosis and pulmonary embolism. The findings indicate that people with CVD have a higher chance of developing VTE, especially those with congenital conditions, though more research is needed for better treatment strategies; for example, while varicose veins can prompt the first occurrence of VTE, they don’t seem to increase the risk of it happening again. Understanding these risks is crucial for improving prevention and treatment options, particularly in identifying high-risk patients who may benefit from medications to prevent blood clots. Who this helps: This helps patients with chronic venous disease and healthcare providers managing their treatment.

Plain English
This study used national registry data from over 5,000 patients to compare outcomes of treating varicose veins in one leg at a time versus both legs simultaneously or in staged procedures. Bilateral same-session treatment was not associated with higher complication rates, and improvement in symptom severity scores was similar across groups. Treating both legs at once appears safe and achieves outcomes equivalent to staged procedures, which may reduce the burden on patients of multiple visits.

Plain English
This study investigated the effectiveness of combining two treatments for varicose veins: the standard saphenous vein ablation and additional procedures to directly treat visible varicose veins. Researchers looked at data from 526 patients and found that those who received the combined treatment experienced more significant reductions in symptoms, with a decrease of 4.20 points in their symptom score compared to a decrease of 3.71 points for those who had only the standard treatment. This is important because it shows that for certain patients, treating both the saphenous vein and visible varicosities can lead to better relief from symptoms. Who this helps: Patients suffering from varicose veins.

Plain English
This study looked at various biological markers in the blood that can help diagnose deep vein blood clots (venous thromboembolism, or VTE) and predict long-term complications from them, like post-thrombotic syndrome (PTS). The researchers found that the D-dimer test is the most reliable marker currently used for this purpose, though other markers like P-selectin and specific cytokines also show promise. Identifying effective biomarkers is important because it can lead to better diagnosis and management of VTE, potentially reducing severe complications. Who this helps: Patients at risk of deep vein thrombosis and their doctors.

Plain English
This research studied a drug called GMI-1271, which targets a specific protein linked to blood clotting, to see if it is safe and effective for treating blood clots without increasing bleeding risk. The study involved healthy volunteers and two patients with deep vein thrombosis (DVT) who showed improvements in their symptoms within 48 hours of treatment, with no serious side effects found. This matters because it suggests a new way to treat dangerous blood clots safely, which could help many patients who currently have limited options. Who this helps: Patients with blood clots, especially those at risk of bleeding.

Plain English
Researchers looked at how to diagnose and treat patients with suspected blood clots during the COVID-19 pandemic. They found that COVID-19-positive patients often had high levels of D-dimer, a protein that indicates clotting problems, leading to increased use of ultrasound and other imaging tests. This is important because better diagnosis and treatment can help prevent serious complications in these patients. Who this helps: This helps doctors and COVID-19 patients at risk of blood clots.

Plain English
This study looked at critically ill patients with severe respiratory issues caused by the H1N1 influenza virus to see if using a blood thinner called heparin could prevent blood clots. The researchers found that patients with H1N1 were 23 times more likely to develop serious blood clots in their lungs, but those treated with heparin had a much lower risk, being 33 times less likely to experience any blood clots compared to those who didn't receive the treatment. This matters because it shows that using heparin can help prevent dangerous clotting without causing bleeding problems. Who this helps: This helps patients with severe H1N1 and doctors treating them.

Plain English
Researchers studied different mouse models to better understand deep vein thrombosis, a condition where blood clots form in veins. They created a clear guide to help scientists choose the right mouse model based on its pros and cons, and included instructions for performing surgeries on these models accurately. This is important because selecting the right model can lead to more effective treatments for venous thrombosis. Who this helps: This helps researchers and medical professionals working to improve treatments for patients with blood clotting issues.

Plain English
This study examined the link between Zika and Chikungunya virus infections and a serious condition called venous thromboembolism, which includes blood clots in veins. Among patients with Zika, 19.4% showed elevated D-dimer levels (a marker for blood clots), while this was seen in 63.8% of patients with Chikungunya. Understanding this connection is important because it can help develop prevention strategies for patients with these viral infections who are at risk for blood clots. Who this helps: This aids doctors in managing and treating patients infected with Zika and Chikungunya.

Plain English
Researchers studied the role of a protein called CD39 in regulating blood clotting and inflammation in deep veins. They found that mice without CD39 developed much larger blood clots and showed increased signs of inflammation compared to normal mice, with 76 inflammatory genes more active in the CD39-deficient mice. This matters because understanding how CD39 controls these processes could lead to better treatments for conditions like deep vein thrombosis, which can cause serious health problems. Who this helps: This benefits patients at risk for blood clots, such as those with deep vein thrombosis.

Plain English
The study examined deep vein thrombosis (DVT) in children, which happens in about 10 to 14 out of every 10,000 hospital admissions for kids each year. It found that, while rare, DVT can lead to serious health issues like lung problems or long-term complications. Recognizing and treating DVT early is crucial for improving the health outcomes of affected children. Who this helps: This helps patients, especially children at risk for DVT, and their doctors.

Plain English
This study focused on how to choose the best mouse models for researching deep vein thrombosis (VT), a condition where blood clots form in the veins. Experts created a step-by-step guide to help researchers select the most suitable mouse model, outlining the pros and cons of different options and providing specific surgical instructions to ensure the techniques used are effective. This is important because selecting the right model can greatly improve the quality of research and lead to better treatments for VT. Who this helps: This helps researchers and doctors working to understand and treat venous thrombosis.

Plain English
This study looked at how veins work in healthy children aged 5 to 17 to understand common issues related to chronic venous disease (CVD). The researchers found that a significant number of children had some type of venous reflux, with about 60% of the youngest group (ages 5-8) showing signs of it, as well as 50% of children aged 9-12, and 57% of teenagers aged 13-17. These findings are important because they highlight that venous reflux is common in children, and understanding this could help doctors monitor and manage potential future health issues related to venous diseases. Who this helps: This research benefits doctors and healthcare providers working with pediatric patients.

Plain English
This study looked at how deep vein thrombosis (DVT) affects the blood and veins in a mouse model. Researchers found that when comparing mice with DVT to healthy mice, certain substances in the blood showed significant differences: levels of adenosine and adenine dropped by about 9.6 and 10.6 times, while l-carnitine levels increased by 67 times. Understanding these distinct changes is important because it could lead to new ways to diagnose and treat DVT more effectively. Who this helps: This benefits patients at risk for DVT by potentially providing better diagnostic tools.

Plain English
This study developed a new mouse model to explore how blood clots in the inferior vena cava (the large vein that carries blood to the heart) can recur. Researchers found that after the first blood clot resolved, the walls of the vein became thicker and showed higher levels of certain proteins, indicating changes that make future clots more likely. Understanding these changes is crucial for finding better treatments for patients at risk of repeated blood clots. Who this helps: This helps patients who have experienced deep vein thrombosis, as well as doctors looking to treat them effectively.

Plain English
This study looked at the outcomes of varicose vein treatments in patients aged 80 and older, compared to younger patients. Researchers analyzed data from over 12,000 procedures and found that octogenarians had significant improvements in their condition after treatment, with an average score improvement of 4.37 (with lower scores indicating less severity) and a patient satisfaction score increase of 8.79. Importantly, these older patients experienced no higher risk of serious complications than younger patients, which highlights that these procedures can be safe and effective for elderly individuals. Who this helps: This research benefits elderly patients suffering from varicose veins, as well as their doctors who can feel more confident in recommending treatment.

Plain English
This study looked at deep vein thrombosis (DVT), a serious condition that can lead to complications like pulmonary embolism and post-thrombotic syndrome (PTS). Researchers found new potential tests and treatments, including biomarkers like ICAM-1 and P-selectin, that could help diagnose these conditions more effectively and lead to better treatment options. Understanding these findings is important because they could improve the way DVT and PTS are managed and reduce risks for patients. Who this helps: Patients at risk for deep vein thrombosis and its complications.

Plain English
This study looked at how a severe infection known as sepsis affects the formation of blood clots in mice. Researchers found that when mice were exposed to toxins similar to those from bacteria, their blood clots became larger and less healthy, mainly due to the activity of certain immune cells and proteins. For example, mice lacking a specific protein called ICAM-1 had smaller clots, showing its importance in this process. Understanding these mechanisms can help in developing treatments to prevent dangerous blood clots in patients suffering from sepsis. Who this helps: This helps patients at risk of blood clots during severe infections, as well as doctors in managing their care.

Plain English
Researchers studied the effectiveness of apixaban compared to warfarin, the current blood-thinning medication, in preventing blood clots around mechanical heart valves in pigs. They found that apixaban led to significantly less thrombus (clot) weight, averaging 357.5 mg, compared to 247.1 mg for warfarin and a control group that had no medication at all which showed an average of 1422.9 mg. This is important because apixaban not only showed good results in preventing clots, but it also did not cause any bleeding complications, which can be a serious issue with warfarin. Who this helps: Patients with mechanical heart valves could benefit from this new treatment option.

Plain English
This study looked at a drug called GMI-1271 that blocks a specific protein (E-selectin) involved in blood clot formation in mice. The researchers found that GMI-1271 significantly reduced the formation of blood clots and inflammation without causing much bleeding—specifically, it resulted in less bleeding compared to a commonly used blood thinner, reducing clot weight and inflammatory cell movement. This is important because it suggests that GMI-1271 could be an effective and safer treatment option for preventing and treating blood clots. Who this helps: This helps patients at risk of venous thrombosis and healthcare providers treating them.

Plain English
This research paper looked into new methods for diagnosing deep vein thrombosis (DVT), a condition that can cause serious health issues. The study found that the D-dimer test, along with a risk assessment tool called the modified Wells score, is effective for excluding DVT in some patients. Additionally, a newer biomarker called soluble P-selectin shows promise for helping to identify DVT cases more accurately. Who this helps: This benefits healthcare providers and patients by improving the accuracy of DVT diagnoses.

Plain English
This study looked at the treatment and results for patients with varicose veins, tracking data from over 1,400 patients treated between January and November 2015. The results showed that patients experienced significant improvements; the average severity of symptoms dropped from 9.39 to 4.71, and overall patient-reported symptoms also improved greatly after treatment. This matters because it shows that modern treatments for varicose veins are effective, leading to better quality of life for patients. Who this helps: This helps patients suffering from varicose veins.

Plain English
This report discusses a meeting where experts evaluated the effectiveness and safety of treatments for chronic venous disease (CVD) in the legs, focusing on their impact on American adults. The panel found that there are significant gaps in evidence about these treatments and identified disparities in how patients are treated, which can lead to worse health outcomes, particularly for those on Medicare. The findings are important because they aim to help improve coverage policies and treatment quality for those suffering from CVD. Who this helps: This helps patients with chronic venous disease and their healthcare providers.

Plain English
The study looked at varicose veins, which are swollen veins affecting many people's quality of life and costing the healthcare system a lot of money. Researchers found that both high pressure in the veins and problems with the valves in those veins play important roles in how varicose veins develop, but the exact cause is still unclear. This is important because understanding the cause could lead to better treatments. Who this helps: This helps patients suffering from varicose veins.

Plain English
This study looked at the outcomes of varicose vein procedures in older patients (65 and above) compared to younger patients (under 65). It found that both age groups showed significant improvements after treatment, with older patients having similar rates of complications and benefits as younger patients. Importantly, all patients experienced better clinical results and reported improvements in symptoms, showing that age shouldn't prevent older individuals from receiving these procedures. Who this helps: This helps patients, especially those over 65 dealing with varicose veins.

Plain English
This study looked at how pneumonia, specifically caused by the bacteria Klebsiella pneumoniae, affects the risk of blood clots in the veins. Researchers found that mice with pneumonia had blood clots that were three times larger than those in healthy mice, and their bodies showed greater levels of certain proteins, called cell-adhesion molecules, that contribute to clot formation. This is important because it suggests that targeting these proteins might help prevent blood clots in patients with pneumonia. Who this helps: Patients with pneumonia at risk of developing blood clots.